Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Sep;58(3):335–340. doi: 10.1038/bjc.1988.214

Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.

R Ganapathi 1, H Schmidt 1, D Grabowski 1, M Melia 1, N Ratliff 1
PMCID: PMC2246592  PMID: 3179186

Abstract

The role of the calmodulin inhibitor trifluoperazine (TFP) in modulating the cellular levels and cytotoxicity in vitro and antitumour effects in vivo of doxorubicin (DOX), was evaluated in progressively DOX-resistant (5- to 40-fold) sublines of B16-BL6 mouse melanoma. In parental-sensitive B16-BL6 cells treated for 3 h, the IC50 of DOX was 0.1 microgram ml-1, and a less than 2-fold enhancement in DOX cell kill in the presence of a noncytotoxic concentration of 5 microM TFP was observed. However, in the DOX-resistant sublines, the IC50 was 0.7 to 5.0 micrograms ml-1 DOX in the absence of 5 microM TFP and 0.3 to 0.7 microgram ml-1 DOX in the presence of 5 microM TFP. The 2- to 7.5-fold decrease in the IC50 of DOX in the presence of 5 microM TFP, was dependent on the level of DOX-resistance in the various sublines. Compared to parental-sensitive cells, a 2-fold decrease in DOX-accumulation was evident only in the 40-fold DOX-resistant subline. Further, maximal enhancement (50%) of cellular DOX accumulation in the presence of 5 microM TFP was observed only in the 40-fold resistant cells treated with 5.0 micrograms ml-1 DOX. Retention of DOX in the 40-fold resistant subline was only 20% lower than similarly treated sensitive cells, and the inclusion of TFP increased DOX retention less than 10-15%. Antitumour studies in mice with experimental pulmonary metastases revealed that although DOX and DOX plus TFP had similar antitumour activity with the parental sensitive B16-BL6 cells, the combination of DOX plus TFP was significantly more effective than DOX alone with the DOX-resistant sublines. No overt toxicity was observed in normal mice treated with doses of TFP, DOX or DOX plus TFP used for in vivo chemotherapy studies. Results from this study suggest that gross cellular DOX levels do not appear to correlate with the magnitude of resistance, and the effects of TFP in modulating DOX resistance is possibly due to mechanisms other than mere alterations in cellular drug accumulation and/or retention.

Full text

PDF
335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bachur N. R., Moore A. L., Bernstein J. G., Liu A. Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods. Cancer Chemother Rep. 1970 Apr;54(2):89–94. [PubMed] [Google Scholar]
  2. Carter S. K. Adriamycin-a review. J Natl Cancer Inst. 1975 Dec;55(6):1265–1274. doi: 10.1093/jnci/55.6.1265. [DOI] [PubMed] [Google Scholar]
  3. Ganapathi R., Grabowski D. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance. Biochem Pharmacol. 1988 Jan 15;37(2):185–193. doi: 10.1016/0006-2952(88)90716-2. [DOI] [PubMed] [Google Scholar]
  4. Ganapathi R., Grabowski D. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 1983 Aug;43(8):3696–3699. [PubMed] [Google Scholar]
  5. Ganapathi R., Grabowski D., Rouse W., Riegler F. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Cancer Res. 1984 Nov;44(11):5056–5061. [PubMed] [Google Scholar]
  6. Ganapathi R., Grabowski D., Schmidt H., Bell D., Melia M. Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells. Cancer Res. 1987 Jul 1;47(13):3464–3468. [PubMed] [Google Scholar]
  7. Ganapathi R., Grabowski D., Schmidt H., Seshadri R., Israel M. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells. Biochem Biophys Res Commun. 1985 Sep 16;131(2):912–919. doi: 10.1016/0006-291x(85)91326-9. [DOI] [PubMed] [Google Scholar]
  8. Ganapathi R., Grabowski D., Turinic R., Valenzuela R. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells. Eur J Cancer Clin Oncol. 1984 Jun;20(6):799–806. doi: 10.1016/0277-5379(84)90219-0. [DOI] [PubMed] [Google Scholar]
  9. Ganapathi R., Yen A., Grabowski D., Schmidt H., Turinic R., Valenzuela R. Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells. Br J Cancer. 1986 Apr;53(4):561–566. doi: 10.1038/bjc.1986.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gerlach J. H., Endicott J. A., Juranka P. F., Henderson G., Sarangi F., Deuchars K. L., Ling V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature. 1986 Dec 4;324(6096):485–489. doi: 10.1038/324485a0. [DOI] [PubMed] [Google Scholar]
  11. Harker W. G., Bauer D., Etiz B. B., Newman R. A., Sikic B. I. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res. 1986 May;46(5):2369–2373. [PubMed] [Google Scholar]
  12. Inaba M., Kobayashi H., Sakurai Y., Johnson R. K. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979 Jun;39(6 Pt 1):2200–2203. [PubMed] [Google Scholar]
  13. Kessel D., Wilberding C. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res. 1985 Apr;45(4):1687–1691. [PubMed] [Google Scholar]
  14. Krishan A., Sauerteig A., Wellham L. L. Flow cytometric studies on modulation of cellular adriamycin retention by phenothiazines. Cancer Res. 1985 Mar;45(3):1046–1051. [PubMed] [Google Scholar]
  15. Miller R. L., Bukowski R. M., Budd G. T., Purvis J., Weick J. K., Shepard K., Midha K. K., Ganapathi R. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol. 1988 May;6(5):880–888. doi: 10.1200/JCO.1988.6.5.880. [DOI] [PubMed] [Google Scholar]
  16. Riordan J. R., Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther. 1985;28(1):51–75. doi: 10.1016/0163-7258(85)90082-8. [DOI] [PubMed] [Google Scholar]
  17. Siegfried J. M., Tritton T. R., Sartorelli A. C. Comparison of anthracycline concentrations in S180 cell lines of varying sensitivity. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1133–1141. doi: 10.1016/0277-5379(83)90039-1. [DOI] [PubMed] [Google Scholar]
  18. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 1978 Jun;38(6):1785–1791. [PubMed] [Google Scholar]
  19. Slater L. M., Murray S. L., Wetzel M. W., Wisdom R. M., DuVall E. M. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest. 1982 Nov;70(5):1131–1134. doi: 10.1172/JCI110702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tsuruo T., Iida H., Nojiri M., Tsukagoshi S., Sakurai Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983 Jun;43(6):2905–2910. [PubMed] [Google Scholar]
  21. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982 Nov;42(11):4730–4733. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES